Klaria Pharma secures SEK 30.7 million bridge financing ahead of rights issue

• Klaria Pharma secured bridge financing agreements totaling SEK 30.7 million to cover near-term payment obligations ahead of a rights issue.
• Bridge lenders included AB Strati, Fenja Capital, Almida Holding, and several individual investors.
• Some bridge lenders committed to subscribe for units in the rights issue; payment may be made via set-off, subject to board approval.
• The rights issue targets gross proceeds of up to SEK 147.6 million; up to SEK 48.7 million could be paid via set-off.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klaria Pharma Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 202610080355BITN____UKPR__SV_20261008-BIT-0634-0) on October 08, 2026, and is solely responsible for the information contained therein.